Pediatrix Medical Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Pediatrix Medical Group, Inc. reported a significant turnaround in 2025, achieving $165.4 million in net income and $275.6 million in Adjusted EBITDA, driven by strategic portfolio optimization and improved same-unit revenue.
NYSE
Pediatrix Medical Group's 2024 10-K filing reveals a strategic shift towards hospital-based and maternal-fetal medicine, alongside challenges including a goodwill impairment and revenue cycle management transformation.
NYSE
Pediatrix Medical Group's 10-K filing details its national physician network, business strategy, and financial performance for the year ended December 31, 2023.